NCT05879250View on ClinicalTrials.gov

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

December 27, 2027

Study Completion Date

December 27, 2028

Conditions
Glioblastoma, IDH-WildtypeMGMT-Unmethylated Glioblastoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

RADIATION

Radiation Therapy

Undergo routine radiation therapy

DRUG

STAT3 Inhibitor WP1066

Given PO

PROCEDURE

Surgical Procedure

Undergo removal or biopsy of tumor

Trial Locations (2)

60555

Northwestern Medicine: Warrenville, Warrenville

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Moleculin Biotech, Inc.
All Listed Sponsors
collaborator

Moleculin Biotech, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT05879250 - WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter